Heapatitis B

• Viread (Tenofovir Disoproxil Fumarate)
• Baraclude (entecavir)
• Epivir-HBV (lamivudine; 3TC)
• Hepsera (adefovir dipivoxil)

• Experimental Treatments

• Other

Heapatitis C

• PegIntron + Rebetol (peginterferon alfa-2b + ribavirin)
• Pegasys + Copegus (peginterferon alfa-2a + ribavirin)

• Experimental Treatments

• Other

Viread (Tenofovir Disoproxil Fumarate)

Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102)
P Marcellin and others. AASLD 2008.

Week 96 Resistance Surveillance for HBeAg Positive and Negative Subjects with Chronic HBV Infection Randomized to Receive Tenofovir DF 300 mg QD
A Snow and others. AASLD 2008.

Tenofovir is Equally Active In Vitro Against Wild-type HBV Clinical Isolates of Genotypes A-H
M Curtis and others. AASLD 2008.

Cost Effectiveness Simulation Analysis of Tenofovir Disoproxil Fumarate (TDF), Lamivudine (LAM), Adefovir Dipivoxil (ADV) and Entecavir (ETV) in HBeAg Negative Patients with Chronic Hepatitis B (CHB) in the USA
B Deniz and others. AASLD 2008.

PRESENCE OF rtA194T AT BASELINE DOES NOT REDUCE EFFICACY TO TENOFOVIR (TDF) IN PATIENTSWITH LAMIVUDINE (LAM)-RESISTANT CHRONIC HEPATITIS B
S Fung and others. AASLD 2008.

Tenofovir Disoproxil Fumarate (TDF) versus Adefovir Dipivoxil (ADV) in Asians with HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B Participating in Studies 102 and 103
S Lee and others. AASLD 2008.

Baraclude (entecavir)

Three Years of Entecavir (ETV) Re-treatment of HBeAg(-) ETV Patients Who Previously Discontinued Treatment: Results from Study ETV-901
D Shouval and others. AASLD 2008.

Five Years of Continuous Entecavir for Nucleoside-naïve HBeAg(+) Chronic Hepatitis B: Results from Studies ETV-022/-901
S Huy and others. AASLD 2008.

Cost Effectiveness Simulation Analysis of Tenofovir Disoproxil Fumarate (TDF), Lamivudine (LAM), Adefovir Dipivoxil (ADV) and Entecavir (ETV) in HBeAg Negative Patients with Chronic Hepatitis B (CHB) in the USA
B Deniz and others. AASLD 2008.

Long-term Entecavir Therapy Results in Reversal of Fibrosis/Cirrhosis and Continued Histologic Improvement in Patients with HBeAg(+) and (-) Chronic Hepatitis B: Results from Studies ETV-022, -027 and -901
Y Liaw and others. AASLD 2008.

Histologic Assessment of Long-term Entecavir Treatment in Chronic Hepatitis B Patients
Y Katano and others. AASLD 2008.

Evaluation of Long-term Entecavir Treatment in Stable Chronic Hepatitis B Patients Switched from Lamivudine Therapy
T Ide and others. AASLD 2008.

Epivir-HBV (lamivudine; 3TC)

Cost Effectiveness Simulation Analysis of Tenofovir Disoproxil Fumarate (TDF), Lamivudine (LAM), Adefovir Dipivoxil (ADV) and Entecavir (ETV) in HBeAg Negative Patients with Chronic Hepatitis B (CHB) in the USA
B Deniz and others. AASLD 2008.

PRESENCE OF rtA194T AT BASELINE DOES NOT REDUCE EFFICACY TO TENOFOVIR (TDF) IN PATIENTSWITH LAMIVUDINE (LAM)-RESISTANT CHRONIC HEPATITIS B
S Fung and others. AASLD 2008.

LAMIVUDINE-RESISTANT MUTATION DETECTED AMONG TREATMENT-NAÏVE HEPATITIS B PATIENTS IS COMMON AND MAY BE ASSOCIATED WITH TREATMENT FAILURE
S Fung and others. AASLD 2008.

Evaluation of Long-term Entecavir Treatment in Stable Chronic Hepatitis B Patients Switched from Lamivudine Therapy
T Ide and others. AASLD 2008.

Hepsera (adefovir dipivoxil)

Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102)
P Marcellin and others. AASLD 2008.

Cost Effectiveness Simulation Analysis of Tenofovir Disoproxil Fumarate (TDF), Lamivudine (LAM), Adefovir Dipivoxil (ADV) and Entecavir (ETV) in HBeAg Negative Patients with Chronic Hepatitis B (CHB) in the USA
B Deniz and others. AASLD 2008.

Tenofovir Disoproxil Fumarate (TDF) versus Adefovir Dipivoxil (ADV) in Asians with HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B Participating in Studies 102 and 103
S Lee and others. AASLD 2008.

Experimental Treatments

none

Other

Estimated Prevalence of Chronic Hepatitis B (CHB) in Foreign-Born (FB) Persons Living in the United States (U.S.) by Country/Region of Origin
S Welch and others. AASLD 2008.

Effect of Efavirenz on the Pharmacokinetics of Ethinyl Estradiol and Norgestimate in Healthy Female Subjects
H. Sevinsky and others. AASLD 2008.

Limited Value of Single ALT Determination for Assessing Chronic Hepatitis B (CHB)
E Heathcote and others. AASLD 2008.

Perception of Chronic Hepatitis B in Asian American Communities
D Salinas-Garcia and others. AASLD 2008.

PegIntron + Rebetol (peginterferon alfa-2b + ribavirin)

Boceprevir Plus Peginterferon alfa-2b/Ribavirin for Treatment of Genotype 1 Chronic Hepatitis C in Previously Untreated Patients: Interim Results from the HCV SPRINT-1 Study
P Kwo and others. AASLD 2008.

Probability of Sustained Virologic Response (SVR) Is Associated With the Magnitude of HCV RNA Reduction at Week 4 of Treatment With Peginterferon (PEG) Plus Ribavirin (RBV): Results of the IDEAL Trial
M Sulkowski and others. AASLD 2008.

Hematologic Safety Data From the IDEAL Trial: Neutropenia, Anemia, and Thrombocytopenia Profiles of Peginterferon alfa/Ribavirin
F Poordad and others. AASLD 2008.

Treatment-Related Anemia Is Associated With Higher SVR Rates Among Persons Treated With Peginterferon (PEG)/Ribavirin (RBV): Results From the IDEAL Study
M Sulkowski and others. AASLD 2008.

Pegasys + Copegus (peginterferon alfa-2a + ribavirin)

Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in treatment-naïve patients with chronic hepatitis C genotype 1 infection given as monotherapy and in combination with peginterferon alfa-2a (P) and ribavirin (R)
M Manns and others. AASLD 2008.

Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in combination therapy with peginterferon alfa-2a (P) and ribavirin (R) for 28 days in P+R treatment-experienced patients with chronic hepatitis C genotype 1 infection
M Manns and others. AASLD 2008.

Hematologic Safety Data From the IDEAL Trial: Neutropenia, Anemia, and Thrombocytopenia Profiles of Peginterferon alfa/Ribavirin
F Poordad and others. AASLD 2008.

Treatment-Related Anemia Is Associated With Higher SVR Rates Among Persons Treated With Peginterferon (PEG)/Ribavirin (RBV): Results From the IDEAL Study
M Sulkowski and others. AASLD 2008.

Experimental Treatments

Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in treatment-naïve patients with chronic hepatitis C genotype 1 infection given as monotherapy and in combination with peginterferon alfa-2a (P) and ribavirin (R)
M Manns and others. AASLD 2008.

Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in combination therapy with peginterferon alfa-2a (P) and ribavirin (R) for 28 days in P+R treatment-experienced patients with chronic hepatitis C genotype 1 infection
M Manns and others. AASLD 2008.

Boceprevir Plus Peginterferon alfa-2b/Ribavirin for Treatment of Genotype 1 Chronic Hepatitis C in Previously Untreated Patients: Interim Results from the HCV SPRINT-1 Study
P Kwo and others. AASLD 2008.

BMS-790052 is a First-in-class Potent Hepatitis C Virus (HCV) NS5A Inhibitor for Patients with Chronic HCV Infection: Results from a Proof-of-concept Study
R Nettles and others. AASLD 2008.

Other

Impact of the Use of Drugs and Substitution Treatments on the Antiviral Treatment of Chronic Hepatitis C: Analysis of Compliance, Virological Response and Quality of Life (CHEOBS)
P Melin and others. AASLD 2008.

Impact of Advanced Fibrosis and Cirrhosis on Sustained Virologic Response of HCV G1-Infected Patients: Results of The Canadian POWeR Program
P Marotta and others. AASLD 2008.

Predicting the Ability to Achieve a Sustained Virologic Response (SVR) in the First 12 Weeks: Results From the IDEAL Study
L Nyberg and others. AASLD 2008.

 

The material posted on HIV and Hepatitis.com about AASLD 2008 is
not approved by nor is it a part of AASLD 2008.